Wuxi Biortus Biosciences, a China contract research organization, recently obtained a $15 million investment led by Bayland Capital, Biortus said in a press release on Friday. Bayland is backed in part by Pharmaron Beijing, whose chairman is billionaire Lou Boliang. (See the press release here.) Pharmaron’s Hong Kong-traded shares have more than doubled in the past year. Healthcare-related businesses were among the largest source of new members on the 2020 Forbes China Rich List released on Nov. 5.

Source: Forbes November 15, 2020 10:30 UTC